RESUMO
BACKGROUND AND OBJECTIVE: In patients with atrial fibrillation following percutaneous coronary intervention, if a proton pump inhibitor is used, could that allow the use of warfarin triple therapy, or is there additional reduction in bleeding while using it with dual therapy? METHODS: The RE-DUAL PCI trial randomized 2725 patients with atrial fibrillation post-percutaneous coronary intervention to dabigatran dual therapy (110 or 150 mg twice daily, with clopidogrel or ticagrelor) or warfarin triple therapy (with clopidogrel or ticagrelor, and aspirin for 1-3 months). This prespecified subgroup analysis evaluated risks of a first major bleeding event or clinically relevant non-major bleeding event, all gastrointestinal bleeding, and a composite efficacy endpoint of all-cause mortality/thromboembolic event or unplanned revascularization according to baseline use of a proton pump inhibitor. RESULTS: Of 2678 analyzed patients, 1641 (61.3%) were receiving a proton pump inhibitor at baseline. Dabigatran 110 and 150 mg dual therapy reduced the risk of major bleeding events or clinically relevant non-major bleeding events vs warfarin triple therapy regardless of proton pump inhibitor use, with comparable risk of the composite efficacy endpoint (all interaction p values > 0.05). For gastrointestinal bleeding, no interaction was observed between study treatment and proton pump inhibitor use (interaction p values 0.84 and 0.62 for dabigatran 110 and 150 mg dual therapy, respectively, vs warfarin triple therapy). CONCLUSIONS: Dabigatran 110 and 150 mg dual therapy reduced the risk of major bleeding events or clinically relevant non-major bleeding events vs warfarin triple therapy, regardless of proton pump inhibitor use at baseline, in patients with atrial fibrillation who underwent percutaneous coronary intervention. Risk of the composite efficacy endpoint appeared to be similar for dabigatran dual therapy vs warfarin triple therapy in patients receiving/not receiving a proton pump inhibitor. CLINICALTRIALS. GOV UNIQUE IDENTIFIER: NCT02164864.
Assuntos
Anticoagulantes/uso terapêutico , Fibrilação Atrial/tratamento farmacológico , Dabigatrana/uso terapêutico , Inibidores da Bomba de Prótons/uso terapêutico , Varfarina/uso terapêutico , Idoso , Fibrilação Atrial/cirurgia , Quimioterapia Combinada , Feminino , Humanos , Masculino , Intervenção Coronária Percutânea/efeitos adversos , Estudos Prospectivos , Inibidores da Bomba de Prótons/administração & dosagemRESUMO
OBJECTIVE: To assess consumption and the exposition of patients admitted to the Universitary Hospital of the Interamerican Open University (UAI), between October and December of 2007-2009. METHODS: Descriptive observational study. The information was obtained of the Pharmacia Sector. We analyze the dispensations (Units); the exposition was evaluated using the defined daily dose per 100 beds/day. We analyzed how many of the psychotropics used were considerated essentials drugs for the WHO. We assessed the adverse drug reactions registered. RESULTS: The psychopharmacological drugs represented the 43%, 41%, and the 44% (period 2007-2009) of the drugs used for the Central Nervous System. The benzodiazepines represented more of the 50% of the psychopharmacological drugs used. The exposure was respectively of 57%, 66%, and 40% (for all the patients admitted to the hospital on period 2007-2009). The essential medicines used fluctuate between 41% and 48%. From 32 adverse reactions connected with the Central Nervous System, 20 (62.5%) were attributed to psychotropics. CONCLUSIONS: 1. We established the quantity of the psychotropics dispensations, as well as the level of the exposure. 2. The psychotropic utilization of the essentials medicines list of the WHO was above 40%.